| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
Phase 3 bunionectomy and open-label safety trials of onzotrigine remain on track for initiation with topline results expected in the second half of 2027 |
| 03 Sep 2026 |
8-K: Results of Operations and Financial Condition
Completed upsized initial public offering, including full exercise of the underwriters’ option to purchase additional shares, raising gross proceeds of $397.4 million; together with existing cash expected to fund operations into 2029 |
| 10 Aug 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Other Events
Latigo Biotherapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: |
Loading...